Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Non-Deal Roadshow (October 2023)
26 slides from Proteomics International Laboratories's roadshow presentation, Oct 30, 2023
Slide 1: ASX Release: Investor Presentation
ASX Release 30 October 2023 ASX code: PIQ Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ) is pleased to release a copy of its latest investor presentation for a non-deal roadshow to institutional investors. Authorised by Dr Richard Li
Slide 2: Investor Presentation - Non-deal Roadshow
ASX: PIQ Proteomics International LABORATORIES LTD Investor Presentation 30 October 2023 Non-deal Roadshow Dr. Richard Lipscombe Managing Director 1
Slide 3: Disclaimer
Disclaimer ASX: PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in
Slide 4: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ A medical technology company at the forefront of precision medicine and predictive diagnostics Three key focus tests driven by a proprietary platform technology: • Proven predictive test for early detection of diabetic kidney disease (DKD) • Being c
Slide 5: Corporate Overview
Corporate Overview ASX: PIQ Corporate Snapshot Financial and Corporate ASX code PIQ Market Capitalisation A$110m • Top 40 Shareholders hold 49% Cash (30 Sept ’23 + ~$1.8m R&D tax incentive due Q4 CY23) $4.9m • Directors are highly aligned with shareholders holding 18% Share Price A$0.90 Shares on is
Slide 6: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 7: Promarker D
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE Asimple blood test for predicting diabetic kidney disease
Slide 8: Problem and Solution – Diabetic Kidney Disease
Problem and Solution – Diabetic Kidney Disease ASX: PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the onset Roadblock of diabetic kidney disease The P
Slide 9: PromarkerD – Simple Integration & Use
PromarkerD – Simple Integration & Use ASX: PIQ Blood sample drawn Biomarkers analysed Results generated by Results and intervention plan PromarkerD Hub software delivered Sample is drawn at clinic or Laboratory uses a standard Cloud based algorithm, the Clinician delivers results to patient patholog
Slide 10: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ Peer Reviewed Physician Support Outperforms Standard of Care PromarkerD tested on over 5,000 Survey of 400 Endocrinologists & • 857 community based patients tested patients in 4-year clinical studies Primary Care Physicians (US based) for existing DKD at baseline: 4
Slide 11: PromarkerD Patented in all Major Markets
PromarkerD Patented in all Major Markets ASX: PIQ Diabetic Kidney Disease is becoming one of the largest burdens on healthcare systems globally Patent family & Trademark covers 72% of world’s diabetics1 45% Country Patent/Application No Patent Status No. Diabetics1 undiagnosed Australia 2011305050 G
Slide 12: United States: Commercialisation in Progress
United States: Commercialisation in Progress ASX: PIQ Sonic Healthcare USA has the exclusive licence to commercialise PromarkerD in the world’s largest healthcare market Over 7,000 Employees Over 300 Sales reps Over 400 pathologists Services over 20 million patients Marketing, Sample collection, Rep
Slide 13: Reimbursement Underway
Reimbursement Underway ASX: PIQ Proteomics International has been working with its partner Sonic Healthcare USA on reimbursement in the US CMS is the federal agency Medicare and Medicaid CMS is responsible for CMS has assigned a in the United States that collectively responsible for providing health
Slide 14: Target Markets
Target Markets: ASX: PIQ Next Steps • Licence with Apacor Ltd for immunoassay test • Engagement with the NHS Supply Chain Tender • Test registered with Medicines & Healthcare products Regulatory Agency • PromarkerD inclusion in the NICE guidelines United Kingdom • National Institute for Health & Car
Slide 15: Pipeline of Precision Diagnostics
Pipeline of Precision Diagnostics ASX: PIQ Platform technology drives deep pipeline of novel diagnostic tests Further global potential in new markets • Promarker™️ platform develops novel intellectual property • Targeting new diagnostic tests in areas of significant unmet need • Enormous markets and
Slide 16: Dx Pipeline: Endometriosis & Oesophageal Cancer
Dx Pipeline: Endometriosis & Oesophageal Cancer ASX: PIQ Proteomics International has two potential world-first blood tests in late-stage development Impact of Endometriosis PromarkerTM for Endometriosis • Endometriosis is a common and painful disease • Prototype test identified up to 90% of patient
Slide 17: Timeline & Milestones
Timeline & Milestones ASX: PIQ FY23 Achievements FY24 Targets & Milestones 29 Aug 2022 14 Dec 2022 OxiDx P/L spin- Generate sales revenue 1 Aug 2022 UK NICE Potential breakthrough out launched for publishes for PromarkerD in the 3 May 2023 blood test able to detect oxidative stress Medtech USA SGLT2
Slide 18: Value Inflection Points
Value Inflection Points ASX: PIQ Share Price Catalysts throughout FY24 Exceptional Global Opportunity Milestone Qtr Dec Mar Jun Impact ➢ Disruptive, cutting-edge technology & proven in-house diagnostics platform PromarkerD First Sales in USA Initiate pathway to significant revenues ➢ PromarkerD test
Slide 19: Peer Comparison
Peer Comparison ASX: PIQ Market FY23 FY23 Net Stock Code Company Focus Share Price Capitalisation Revenue Profit/Loss Proteomics Predictive blood test measuring novel protein biomarkers for DKD; simple, cost effective, commercial ready. International PIQ.ASX Pipeline of novel diagnostic tests in dev
Slide 20: Contact
Contact ASX: PIQ Dr Richard Lipscombe Dirk van Dissel Managing Director Investor Relations & Corporate Advisor T:+61 8 9389 1992 Candour Advisory E: enquiries@proteomicsinternational.com T:+61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au Kyle Moss Corporate Advisor Euro
Slide 21: Supplemental
Supplemental ASX: PIQ 20
Slide 22: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), Non-Executive Chair Seasoned finance professional with over 30 years’ experience providing corporate advice to Boards of public and private companies. South & He was Co-Founder and MD of Torridon Partners, an i
Slide 23: PromarkerD: World Class Advisory Board
PromarkerD: World Class Advisory Board ASX: PIQ Proteomics International is supported by an international, highly acclaimed advisory board Professor Tim Davis MedSc, MB, W.Aust., DPhil Oxf., Associate Professor Michael Shanik MD, FACP, FACE FRACP, MRCP (UK) – Australia – United States Consultant phy
Slide 24: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention ASX: PIQ How PromarkerD results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Ann
Slide 25: New Treatments to Slow DKD
New Treatments to Slow DKD ASX: PIQ US$7bn of sales in 2020 from the gliflozin class of type 2 diabetes drugs (SGLT2-inhibitors PromarkerD has the potential to become a new standard of care and change clinical practice Janssen collaboration assessed effect of SGLT2-inhibitor (gliflozin) vs placebo o
Slide 26: PromarkerD: Key Publications
PromarkerD: Key Publications ASX: PIQ PromarkerD Demonstrates Benefit of Peters KE, et al. Canagliflozin Attenuates PromarkerD Diabetic Kidney Disease Risk Prediction Score. J Clinical Early Treatment with SGLT2-inhibitors Medicine. 2023. Fusfeld L, et al. Evaluation of the clinical utility of the P
Proteomics International Laboratories — Non-Deal Roadshow (October 2023) on 6ix